Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $602.82, up 0.10%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MDGL shares have gain 10.37% over the last week, with a monthly amount glided 2.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock has seen the most recent analyst activity on November 05, 2025, when Cantor Fitzgerald upgraded its rating to an Overweight. Previously, BofA Securities upgraded its rating to Neutral on November 03, 2025, and kept the price target unchanged to $445. On October 15, 2025, Truist initiated with a Buy rating and assigned a price target of $580 on the stock. B. Riley Securities upgraded its rating to a Buy and raised its price target to $422 on February 28, 2025. H.C. Wainwright reiterated a Buy rating for this stock on February 27, 2025, and upped its price target to $405. In a note dated June 28, 2024, Cantor Fitzgerald initiated a Neutral rating.
Madrigal Pharmaceuticals Inc [MDGL] stock has fluctuated between $265.00 and $609.98 over the past year. Currently, Wall Street analysts expect the stock to reach $706.17 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $602.82 at the most recent close of the market. An investor can expect a potential return of 17.14% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] reported sales of 740.64M for the trailing twelve months, which represents a growth of 362.03%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.38 and Total Capital is -0.38. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 597.79 points at the first support level, and at 592.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 611.43, and for the 2nd resistance point, it is at 620.03.
Ratios To Look Out For
For context, Madrigal Pharmaceuticals Inc’s Current Ratio is 3.44. In addition, the Quick Ratio stands at 3.26 and the Cash Ratio stands at 0.97. Considering the valuation of this stock, the price to sales ratio is 18.49, the price to book ratio is 21.87.
Transactions by insiders
Recent insider trading involved FRIEDMAN PAUL A, Director, that happened on Dec 10 ’25 when 24800.0 shares were sold. Director, Taub Rebecca completed a deal on Dec 10 ’25 to sell 18650.0 shares. Meanwhile, Director PAUL FRIEDMAN bought 49600.0 shares on Dec 10 ’25.
